Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
IMDX•Merger agreement amended
- Insight Molecular Diagnostics Inc. said it entered Amendment No. 2 to the merger agreement on Sept. 15, 2026, according to an SEC filing.
- Chronix equity holders will receive a 10% royalty for sales of CNI Monitor, according to the filing.
